Gene Therapy for Fanconi Anemia

Status Terminated

Clinical Trial Summary

This clinical trial will access the toxicity and efficacy of infusion of gene modified cells for patients with Fanconi anemia (FA). Infusion of autologous patient blood stem cells that have been corrected in the laboratory by introduction of the normal gene may improve blood counts in patients with FA.

Clinical Trial Description

OUTLINE: STEM CELL MOBILIZATION FOR CELL COLLECTION: Patients receive filgrastim subcutaneously (SC) twice daily (BID) for up to 6 days (on days 1-6 of mobilization). Patients receive plerixafor SC once daily (QD) on days 4-6 of mobilization. Peripheral blood stem cell (PBSC) count will be checked daily starting on day 4 of mobilization. Patients who have a PBSC count of >= 5 CD34+ cells/mcL will undergo up to 2 apheresis collections on consecutive days. BONE MARROW HARVEST FOR CELL COLLECTION: Patients with inadequate PBSC counts undergo bone marrow harvest for collection of stem/progenitor cells. REINFUSION: Patients receive methylprednisolone intravenously (IV) or prednisone orally (PO) on days -1 to 7 followed by a rapid taper over approximately 1 week and undergo reinfusion of genetically modified hematopoietic stem/progenitor cells on day 0. After completion of study treatment, patients are followed up periodically for 15 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01331018
Study type	Interventional
Source	Fred Hutchinson Cancer Center
Contact
Status	Terminated
Phase	Phase 1
Start date	February 22, 2012
Completion date	February 15, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02931071` - Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1	Phase 2
Terminated	`NCT01319851` - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Recruiting	`NCT00084695` - Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases	Phase 2
Completed	`NCT00000603` - Cord Blood Stem Cell Transplantation Study (COBLT)	Phase 2
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Recruiting	`NCT01146210` - Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia	N/A
Completed	`NCT01082133` - Multicenter Transplant Study for Fanconi Anemia	Phase 2
Completed	`NCT00965666` - Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia	Early Phase 1
Terminated	`NCT00290628` - Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	N/A
Recruiting	`NCT00027274` - Cancer in Inherited Bone Marrow Failure Syndromes
Terminated	`NCT01001598` - Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita	Phase 1/Phase 2
Recruiting	`NCT03206086` - Eltrombopag for People With Fanconi Anemia	Phase 2
Recruiting	`NCT03579875` - T Cell Receptor α/β TCD HCT in Patients With Fanconi Anemia	Phase 2
Recruiting	`NCT05598515` - Time-restricted Feeding to Reduce Inflammation in Fanconi Anemia	N/A
Active, not recruiting	`NCT03476330` - Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia	Phase 2
Terminated	`NCT05910853` - Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia
Completed	`NCT03609840` - Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed	`NCT00479115` - Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100	Phase 1/Phase 2
Completed	`NCT00352976` - TBI Dose De-escalation for Fanconi Anemia	Phase 2/Phase 3
Terminated	`NCT03600909` - A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia	Phase 2